Nav: Home

Knowing risk factors could help catch melanomas

November 09, 2016

The new study, published online today by JAMA Dermatology, identifies high risk patients who may benefit from tailored surveillance.

The incidence of melanoma that occurs on the skin is increasing in predominantly white-skinned populations and Australia's incidence is among the highest in the world.

The study's objective was to characterise melanoma patients and the clinical features associated with their melanomas according to patient risk factors: many moles, a history of previous melanoma, and family history of melanoma, to improve the identification and treatment of a higher-risk subgroup.

The researchers classified 2727 patients with melanoma from the Melanoma Patterns of Care Study as having high or lower risk, depending on whether they already had a personal or family history of melanoma, or many moles, or none of these three factors.

Thirty nine (39) per cent of patients were defined as higher risk due to family history, multiple primary melanomas or having lots of moles. The most common risk factor in this group was having many moles, followed by a personal history and a family history.

The authors report the average age at diagnosis was younger for higher-risk patients (62 versus 65 years) compared with those patients at lower risk because they did not have these risk factors. However, that age differed by risk factor: 56 years for patients with a family history, 59 years for those with many moles and 69 years for those with a previous melanoma.

Also, higher-risk patients with many moles were more likely to have melanoma on the trunk of the body, those with a family history were more likely to have melanomas on the limbs, and those with a personal history were more likely to have melanoma on the head and neck.

Dr Watts stated: "The results of our study suggest that a person's risk factor status might be used to tailor their surveillance program in terms of starting age and education about skin self-examination or more intensive surveillance. For instance, doctors could encourage people with many moles or with a family history of melanoma to start skin self-examination and monitoring at an earlier age than other people, and discuss the body sites that require particular attention."

Limitations of the study include risk factors based on physician recall and patient medical records. The authors also did not assess the reliability or validity of the risk factor data.
-end-


University of Sydney

Related Melanoma Articles:

B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer.
Five things to know about melanoma
'Five things to know about ... melanoma' in CMAJ (Canadian Medical Association Journal) provides a brief overview of this malignant skin cancer for physicians and patients.
Describing aspects of melanoma progression
Three related articles and an editorial focus on various aspects of melanoma progression.
Is your melanoma hot enough for immunotherapy?
University of Colorado Cancer Center study presented at AACR 2019 shows that tumors with mutations in genes leading to over-activation of the NF-kB signaling pathway were more than three times as likely to respond to anti-PD1 immunotherapy compared with tumors in which these changes were absent.
BU researchers discover therapeutic target of melanoma
Researchers have identified a biomarker and a possible new therapy for melanoma.
Seawater bacteria provides leads to fight melanoma
Malignant melanoma can be a particularly dangerous form of cancer, and more therapeutic options are needed.
New drug combination could be more effective against melanoma
A new study from MIT suggests that combining kinase inhibitors with experimental drugs known as ribonucleases could lead to better results.
Targeting MC1R in metastatic melanoma
University of Colorado Cancer Center study describes a molecule that seeks out melanoma cells, for imaging and potentially for therapy.
How melanoma evades targeted therapies
New research shows how metastatic melanoma becomes resistant to a common class of targeted therapy.
Fishing for new leads in a rare melanoma
Many cancers arise from a double hit: activation of a tumor-promoting gene plus loss of a tumor suppressor gene.
More Melanoma News and Melanoma Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.